2-叔丁基-4-氨基苯酚 | 4151-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-叔丁基-4-氨基苯酚
• 英文名称: 4-amino-2-(tert-butyl)phenol
• 英文别名: 2-tert-Butyl-4-aminophenol；4-Amino-2-tert-butyl-phenol；4-amino-2-tert-butylphenol
• CAS: 4151-62-6
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: LJXDFLGENKUMOA-UHFFFAOYSA-N

物化性质

• 熔点：
  93.0-93.5 °C
• 沸点：
  290.6±33.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-叔丁基-4-氨基苯酚 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 反应 48.5h， 生成 N-[3-tert-butyl-5-(diethylaminomethyl)-4-hydroxyphenyl]acetamide
  参考文献：
  名称：

  Antimalarial drugs. 61. Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-alkylphenols and their N.omega.-oxides

  摘要：

  A series of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-alkylphenols and their N omega-oxides were synthesized by the condensation of 4,7-dichloroquinoline and 4,7-dichloroquinoline N omega-oxide with appropriately substituted 4-amino-2-[(diethylamino)methyl]-6-alkylphenol dihydrochlorides. The latter precursors were prepared in a six-step synthesis starting from available 2-alkylphenols. Several of the title compounds display potent antimalarial activity in mice.

  DOI：

  10.1021/jm00388a027
• 作为产物：
  描述：

  2-叔丁基苯酚 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， -20.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 2-叔丁基-4-氨基苯酚
  参考文献：
  名称：

  Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists

  摘要：

  3-(tert-Butyl)-4-hydroxyphenyl 2,4-dichlorobenzoate (1) was discovered in our in-house high throughput screening as a moderate FXR antagonist. To improve the potency and the stability of the hit 1, forty derivatives were synthesized and SAR was systematically explored. The results turn out that replacing the 2,4-dichlorophenyl with 2,6-dichloro-4-amidophenyl shows great improvement in potency, replacing the benzoate with benzamide shows improvement in stability and slight declining of potency and 3-(tert-butyl)-4-hydroxyphenyl unit is essential in obtaining the FXR antagonistic activity. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.08.021

文献信息

• Novel compounds that are ERK inhibitors
  申请人：Deng Yongqi

  公开号：US20070232610A1

  公开（公告）日：2007-10-04

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及一种化学式1.0的ERK抑制剂，以及其药学上可接受的盐和溶剂。其中，Q为一个哌啶或哌嗪环，可以有一个桥或一个融合环。哌啶环中可以在环中有一个双键。所有其他取代基如定义所述。本发明还涉及使用化合物1.0治疗癌症的方法。
• Compounds that are ERK inhibitors
  申请人：Schering Corporation

  公开号：US07807672B2

  公开（公告）日：2010-10-05

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  公开的是式子1.0的ERK抑制剂及其药学上可接受的盐和溶剂。Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环中有双键。所有其他取代基的定义如本文所述。还公开了使用式子1.0的化合物治疗癌症的方法。
• Design and Optimization of 1<i>H</i>-1,2,3-Triazole-4-carboxamides as Novel, Potent, and Selective Inverse Agonists and Antagonists of PXR
  作者：Yongtao Li、Wenwei Lin、Sergio C. Chai、Jing Wu、Kavya Annu、Taosheng Chen

  DOI：10.1021/acs.jmedchem.2c01640

  日期：2022.12.22

  selective and the most potent inverse agonist and antagonist of PXR, with low nanomolar IC50 values for binding and cellular activity. Importantly, compound 89, a close analog of 85, is a selective and pure antagonist with low nanomolar IC50 values for binding and cellular activity. This study has provided novel, selective, and most potent PXR inhibitors (a dual inverse agonist/antagonist and a pure antagonist)

  孕烷 X 受体 (PXR) 是药物代谢的关键调节因子。许多药物结合并激活 PXR，导致药物不良反应。这表明PXR抑制剂具有治疗价值，但迄今为止缺乏有效的PXR抑制剂。在此，我们报告了一系列 1 H -1,2,3-三唑-4-甲酰胺化合物的结构优化，从而发现化合物85作为 PXR 的选择性且最有效的反向激动剂和拮抗剂，具有低结合和细胞活性的纳摩尔 IC 50值。重要的是，化合物89是85的密切类似物，是一种选择性纯拮抗剂，其结合和细胞活性具有低纳摩尔 IC 50值。这项研究为基础研究和未来的临床研究提供了新型、选择性和最有效的 PXR 抑制剂（双重反向激动剂/拮抗剂和纯拮抗剂），并揭示了如何降低化合物与 PXR 的结合亲和力。
• Aromatic amine resins, their production process and thermosetting resin compositions making use of the same
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0311387A2

  公开（公告）日：1989-04-12

  Disclosed herein is an aromatic amine resin formed of a mixture of aromatic amine compounds represented by the following general formula (a): wherein A means a phenylene, alkyl-substituted phenylene, diphenylene, diphenyl ether or naphthylenyl group, R¹ denotes a halogen atom or a hydroxyl, C1-4 alkoxy or C1-5 alkyl group, ℓ stands for 1 or 2, m is an integer of 0-3, when m is 2 or 3, R¹s may be the same or different and two of R¹s may join together into a 5- to 6-membered alicyclic moiety which may optionally contain one or more side chains, and n stands for an integer of 0-300.

  本发明公开了一种芳香胺树脂，该树脂由以下通式(a)代表的芳香胺化合物混合物形成： 其中 A 表示亚苯基、烷基取代亚苯基、二苯基、二苯醚或萘基，R¹ 表示卤素原子或羟基、C1-4 烷氧基或 C1-5 烷基，ℓ 表示 1 或 2，m 为 0-3 的整数、当 m 为 2 或 3 时，R¹ 可相同或不同，两个 R¹ 可连接成 5 至 6 元脂环分子，该分子可选择包含一条或多条侧链，n 代表 0 至 300 的整数。
• 2-Ureido-benzamide derivatives
  申请人：GRELAN PHARMACEUTICAL CO., LTD.

  公开号：EP0742208A1

  公开（公告）日：1996-11-13

  This invention relates to 2-ureido-benzamide compounds of the formula : in which R1 is H, halogen atom, (C1-C4)alkyl, (C1-C4)alkoxy or (C1-C4)dialkylamino and R2 is H, halogen atom, hydroxy, nitro, (C1-C4)alkyl, (C1-C4)alkoxy or -(CH2)jNR3R3, wherein j is an integer of from 0 to 2, R3 and R4 are each independently H, (C1-C4)alkyl, (C1-C4)alkylsulfonyl or (C1-C4)alkylcarbamoyl, or R3 and R4 taken together with the N-atom to which they are linked can form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring ; X is a (C3-C15)alkyl or -(CH2)kNR5R6 group, wherein k is an integer of from 1 to 4 and R5 and R6 are each independently H, (C1-C6)alkyl or (C1-C4)alkoxycarbonyl ; and, Y is H or (C1-C4)alkyl and Z is or -(CH2)m―A2 wherein m is an integer of from 0 to 4, Q is -CH2- or -CH2CH2-, A1 is phenyl, benzyl, diphenylmethyl, pyridyl, imidazolyl, imidazolythio, dibenzoxepinyl or phenoxycarbonyl optionally carrying halogen atom, hydroxy, (C1-C7)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxymethyl, phenyl or halogenophenyl, A2 is phenyl, benzyl, diphenylmethyl, imidazolylthio, dibenzoxepinyl or phenoxycarbonyl optionally carrying halogen atom, hydroxy, (C1-C7)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxymethyl, phenyl or halogenophenyl, R7 is H or (C1-C4)alkyl and R8 is (C1-C4)alkyl, or R7 and R8 taken together with the C-atom to which they are linked can form a cyclopentyl, cyclohexyl or cycloheptyl ring ; or, Y and Z taken together with the N-atom to which they are linked can form a ring wherein n is an integer of from 1 to 3 and B is phenyl, diphenylmethyl or dibenzocycloheptenyl optionally carrying halogen atom or (C1-C4)alkoxy ; and pharmaceutically acceptable acid addition salts thereof. Those compounds are useful as acyl-CoA:cholesterol acyltransferase inhibitors.

  本发明涉及式.的 2-脲基苯甲酰胺化合物： 其中 R1 是 H、卤素原子、(C1-C4)烷基、(C1-C4)烷氧基或 (C1-C4)二烷基氨基，R2 是 H、卤素原子、羟基、硝基、(C1-C4)烷基、(C1-C4)烷氧基或 -(CH2)jNR3R3，其中 j 是 0 至 2 的整数、R3 和 R4 各自独立地为 H、(C1-C4)烷基、(C1-C4)烷基磺酰基或(C1-C4)烷基氨基甲酰基，或 R3 和 R4 与它们连接的 N 原子一起可形成吡咯烷、哌啶、吗啉、咪唑或吡唑环； X 是(C3-C15)烷基或-(CH2)kNR5R6 基团，其中 k 是 1 至 4 的整数，R5 和 R6 各自独立地是 H、(C1-C6)烷基或(C1-C4)烷氧羰基；以及 Y 是 H 或 (C1-C4) 烷基，Z 是 或-(CH2)m-A2 其中，m 是 0 至 4 的整数，Q 是-CH2-或-CH2CH2-，A1 是苯基、苄基、二苯甲基、吡啶基、咪唑基、咪唑硫基、二苯并氧杂环庚基或苯氧羰基，可选择带有卤素原子、羟基、(C1-C7)烷基、(C1-C4)烷氧基、(C1-C4)烷氧基甲基、苯基或卤素苯基，A2 是苯基、苄基、二苯甲基、咪唑硫基、二苯并氧杂环庚基或苯氧羰基、R7 是 H 或 (C1-C4)烷基，R8 是 (C1-C4)烷基，或 R7 和 R8 与它们连接的 C 原子一起可形成环戊基、环己基或环庚基环；或 Y 和 Z 与它们连接的 N 原子一起可形成一个环 其中 n 为 1 至 3 的整数，B 为苯基、二苯甲基或二苯并环庚烯基，可选择携带卤素原子或（C1-C4）烷氧基；及其药学上可接受的酸加成盐。 这些化合物可用作酰基-CoA：胆固醇酰基转移酶抑制剂。